Histrelin acetate, sold under the brand name Supprelin among others, is a nonapeptide analogue of gonadotropin-releasing hormone (GnRH) with added potency.

A 12-month subcutaneous implant (Supprelin LA) for central precocious puberty (CPP) was approved in May 2007, by the US Food and Drug Administration.

Histrelin can be part of the primary care protocol in transgender children/youth, which is an off-label use in the USA[5] and the UK,[6] and is used in suppressing cis-sex puberty, until the patient is ready to begin cross-sex hormonal therapy.

[7] Common side effects include headache, hot flashes, constipation, reduced libido, gynecomastia, insomnia, renal impairment, weight loss, testicular atrophy, and erectile dysfunction.

Since LH and FSH stimulate the gonads to produce estrogens and androgens in females and males respectively, histrelin can effectively be used to decrease the sex steroids in the blood of patients.